九州通：子公司药品盐酸异丙嗪注射液获注册证书

Core Viewpoint - The company announced that its subsidiary, Beijing Jingfeng Pharmaceutical Group Co., Ltd., received approval from the National Medical Products Administration for the registration of Isopropamide Iodide Injection, indicating a significant advancement in its product portfolio [1] Group 1 - The approved drug, Isopropamide Iodide Injection, is an antihistamine used for treating skin and mucosal allergies, motion sickness, and as an adjunct treatment before and after anesthesia, as well as for preventing radiation sickness or drug-induced nausea and vomiting [1] - As of the date of the announcement, the company has invested approximately RMB 4.67 million (unaudited) in the research and development of this drug [1]